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 Retinitis pigmentosa (RP) is a heterogeneous group of
inherited retinal degenerative diseases, characterized by the
progressive death of rod and cone photoreceptors leading to
an irreversible loss of visual function. The retinal degenera-
tion (rd1) mouse is an appropriate model for studying the cel-
lular and molecular events leading to photoreceptor death and
for evaluating new treatments as the pattern of photoreceptor
loss is similar to that in affected humans and because the mu-
tated gene encodes rod cGMP-phosphodiesterase (Pde6b) [1]
as in some affected human families [2].
However, to this day, mechanisms leading to photorecep-
tor apoptosis are still unclear. Despite the lack of knowledge
of these mechanisms, several therapeutic approaches have been
proposed and showed some efficacy in such a model. Besides
therapies aimed at curing the genetic anomaly per se (correc-
tive gene therapy), many works have demonstrated the ben-
efit of using trophic factors to limit or to postpone the degen-
eration process [3-6]. This appears as a potential mutation-
independent therapeutic approach addressing the challenges
linked to the tremendous genetic heterogeneity associated with
the RP phenotype [7]. We previously demonstrated that in-
traocular administration of glial cell line-derived neurotrophic
factor (GDNF) not only significantly slows down photorecep-
tor degeneration, but also partially preserves visual function
in the rd1 mouse [8]. This result was further confirmed in sev-
eral different models of photoreceptor degeneration in vivo:
the transgenic S334ter rat expressing a mutated rhodopsin gene
[9], the retinal detachment-induced photoreceptor degenera-
tion model [10] and the RCS rat [11]. Yet, the mechanisms of
such neuroprotection remain elusive. The work presented here
stems from an attempt to elucidate one of the mechanisms of
GDNF-induced neuroprotection.
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Purpose: We previously demonstrated that exogenous glial cell line-derived neurotrophic factor (GDNF) induces histo-
logical and functional protection of photoreceptors in the retinal degeneration (rd1) mouse model. The mechanisms un-
derlying such neuroprotection remain elusive. In parallel to this work, we provided evidence for the occurrence of glutamate-
mediated excitotoxic phenomena contributing to rod photoreceptor death in the rd1 retina in the companion paper. In the
present study, we investigated whether, as demonstrated in other models, GDNF could exert its neuroprotective effect on
photoreceptors through Müller glial cells (MGC) by promoting the expression of the glial L-glutamate/L-aspartate trans-
porter (GLAST), an endogenous neuroprotective mechanism against glutamate-mediated excitotoxicity.
Methods: Reverse transcription-polymerase chain reaction (RT-PCR) was used to compare the mRNA expression levels
of GDNF receptors between rd1 and wild-type mouse retinas as well as between MGC and mixed retinal cell cultures.
Recombinant GDNF was applied to pure MGC cultures, to rd1 retinal organ cultures and injected subretinally into rd1
mouse eyes. GLAST expression following GDNF treatment was measured by RT-PCR, immunoblotting and immunohis-
tochemistry. Free glutamate and glutamine levels were quantified in rd1 retinas after GDNF or control treatment using an
amino acid analyzer.
Results: mRNA expression studies of GDNF receptors, GFRα-1 and Ret, demonstrated that GDNF receptors were not
exclusively expressed by the degenerating photoreceptor cells but mainly by MGC. Exogenous GDNF application to
MGC cultures, rd1 mouse retinal explants and in vivo rd1 mouse retinas increased the expression of GLAST by 48% in
retinal explants (p<0.005) and by 25% in vivo (p<0.0005). GLAST protein expression in MGC was particularly increased
around degenerative photoreceptors. Free glutamate and glutamine levels in the rd1 retina were not significantly modified
by exogenous GDNF.
Conclusions: Our data suggest that, in the rd1 mouse retina, GDNF neuroprotective effect on photoreceptors can be
mediated indirectly through the activation of MGC. We demonstrate that injection of recombinant GDNF enhances the
expression of GLAST and more particularly around the degenerating photoreceptors. Since we failed to demonstrate that
GDNF decreases free glutamate levels, we could not ascertain whether GDNF promoted photoreceptor-survival via an
increase of glutamate uptake and, therefore, a change in glutamate distribution.
677It is not formally known whether GDNF acts directly or
indirectly on photoreceptors in vivo and what changes are in-
duced by such a treatment in the dystrophic retina. Whereas
other trophic factors are highly suspected to promote photore-
ceptor survival indirectly through an activation of Müller glial
cells (MGC) [12-15], GDNF was first reported to promote
newborn photoreceptor survival directly in vitro [16-18].
Harada et al. [19,20] demonstrated that GDNF modulates
trophic factor release by MGC in vitro and thus proposed that
GDNF could exert its neuroprotective effect through both di-
rect and indirect pathways.
In the central nervous system (CNS), GDNF has been
shown to protect from excitotoxic and ischemic damage
[21,22], and to modulate the expression of the glutamate trans-
porter GLT-1 [23,24] and/or of the glial L-glutamate/L-aspar-
tate transporter (GLAST) [24,25]. In the retina, GLAST is
expressed in MGC and is essential for glutamate clearance to
avoid neurotoxicity and to allow normal signal transmission
between photoreceptor and bipolar cells [26-29]. Since we
demonstrated, in a parallel companion article, the occurrence
of glutamate-mediated excitotoxic mechanisms contributing
to rod cell death in the rd1 retina [30], we here tried to learn
whether GDNF could exert its neuroprotective effect on pho-
toreceptors through MGC by promoting the expression of
GLAST.
We first studied GDNF receptor distribution by analyz-
ing the mRNA expression of its different components: GFRα-
1 and Ret in wild-type and rd1 mouse retinas, and in MGC
cultures and mixed retinal cell cultures. Since our results dem-
onstrated that GFRα-1 and Ret are expressed in MGC, we
subsequently compared GLAST expression levels in MGC
cultures in the presence and the absence of GDNF, and in
GDNF-treated and PBS-treated rd1 retinas. Finally, we mea-
sured free glutamate and glutamine levels in GDNF- and PBS-
treated rd1 retinas.
METHODS
Animals:  C3H/He mice (rd1 mice) and C57BL/6 mice (wild-
types or controls) were obtained from Iffa Credo (L’Arbresle,
France). Animals were cared for and handled according to the
Association for Research in Vision and Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmic and
Vision Research. They were maintained in clear plastic cages
and subjected to light/dark cycles of 12 h. Day of birth was
designated postnatal day 0 (PN0).
MGC cultures and GDNF application in vitro:  Retinal
MGC culture technique was adapted from Hicks and Courtois
[31]. Since the mutated Pde6b gene has been shown to be
specifically expressed in rod photoreceptors from PN8 in the
rd1 retina [32], we assumed that rd1 and wild-type MGC are
similar in both strains before the degeneration starts, and used
C57BL/6 retinas to perform the cultures. Mice were killed at
PN8. Eyes were immediately enucleated into Dulbecco’s
Modified Eagle’s Medium (DMEM, Invitrogen, Carlsbad, CA)
containing 10 U/ml penicillin and 10 µg/ml streptomycin, and
stored overnight at room temperature in the dark. Eyes were
then incubated in DMEM containing 0.1% trypsin and 70 U/
ml collagenase (Worthington Biochemical, Freehold, NJ) at
37 °C for 30 min. Retinas were dissected free of the retinal
pigment epithelium, cut into 1 mm2 fragments, placed in a
Petri dish containing DMEM supplemented with 10% fetal
bovine serum (Invitrogen, Carlsbad, CA) and maintained at
37 °C in a humidified 5% CO2 incubator. Two days later, reti-
nal aggregates were removed. At confluence, MGC cultures
were resuspended and seeded in two different plates. After
two days (just before confluence) the medium was removed,
and plates were rinsed twice with DMEM. After rinsing, cells
were immediately placed in DMEM supplemented with 5 µg/
ml insulin, 5 µg/ml transferrin, 5 ng/ml sodium selenite, 1
mM sodium pyruvate, 10 U/ml penicillin and 10 µg/ml strep-
tomycin, with or without 50 ng/ml GDNF (rhGDNF, Promega,
Madison, WI). The medium was removed 24 h later, cells were
rinsed with phosphate buffered saline (PBS), and RNA was
extracted.
Retinal cell cultures:  Mouse retinal cell cultures were
prepared from PN8 C57BL/6 mice as previously described
[33].
Retinal organ cultures:  rd1 mice were killed at PN15
(n=6). Retinas were immediately dissected free of the retinal
pigment epithelium and the sclera under a dissecting stere-
omicroscope. Retinal explants were then grown as organ cul-
tures in a chemically defined medium (CDM, 1.5 ml/retina)
in the presence (right eyes) or absence (left eyes) of GDNF
(50 ng/ml). CDM was composed of DMEM, supplemented
with 5 µg/ml insulin, 5 µg/ml transferrin, 63.6 nM progester-
one, 0.1 mM putrescine, 5 ng/ml sodium selenite, 3 mM tau-
rine, 2.7 µM cytidine 5'-diphosphoethanolamine, 5.2 µM cy-
tidine 5'-diphosphocholine, 0.55 µM hydrocortisone, 2.9 µM
3-3'-5-triiodo-L-thyronine, 1 mM sodium pyruvate, 0.31 µM
prostaglandin D2, 10 U/ml penicillin, and 10 µg/ml strepto-
mycin. Cultures were maintained at 37 °C in a humidified 5%
CO2 incubator. After 48 h of incubation, the medium was re-
moved and proteins extracted from the retinas. The left and
right eyes of each animal were compared for the protein ex-
pression study.
Subretinal injections of GDNF:  GDNF was injected into
rd1 mice at PN15 (n=6). Mice were anesthetized intraperito-
neally with a 1:1 (v/v) mixture of etomidate (0.5 mg/ml;
Janssen-Cilag, Boulogne-Billancourt, France) and midazolam
(0.5 mg/ml; Roche, Neuilly-sur-Seine, France) at a dose of 10
ml per kg body weight. GDNF (1 µl) was injected at a dose of
330 ng/µl in sterile PBS with a 10 µl microsyringe (Unimetrics,
Folsom, CA), a microinjector (UltraMicroPump II-Micro 4,
World Precision Instruments, Sarasota, FL) and a 30 gauge
bevelled needle. With the aid of a stereomicroscope (Zeiss,
Germany), the needle was inserted just posterior to the lim-
bus, through the sclera and directed towards the posterior pole
of the eye into the subretinal space. PBS (1 µl) was injected
into the contralateral eye as a control. The left and right reti-
nas of each animal were compared, 48 h after injection, for
the protein expression study.
Reverse transcription-polymerase chain reaction (RT-
PCR) analysis:  Total RNAs were purified from cultures by
use of a Qiagen RNeasy Kit (Qiagen, Valencia, CA) accord-
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ing to the manufacturer’s instructions, and from retinas by the
cesium chloride centrifugation method [34]. cDNAs were syn-
thesized by reverse transcription using random hexamers
(pdN6) according to standard protocols. The sequence of each
primer, the annealing temperatures, the length of the ampli-
fied products and the GenBank accession numbers are given
in Table 1.
Standard PCRs were performed at a final concentration
of 1X PCR buffer, 260 µM dNTPs, 2 µM each primer, 2.5 U
of Taq polymerase (Invitrogen, Carlsbad, CA) in a total vol-
ume of 25 µl. The mixture was amplified with the RoboCycler-
Gradient-96 (Stratagene, La Jolla, CA) for 35 cycles. Cycling
conditions were as follows: initial denaturation at 95 °C for 5
min, then 35 cycles of denaturation at 95 °C for 30 s, anneal-
ing for 30 s (see Table 1 for annealing temperatures) and elon-
gation at 72 °C for 1 min, followed by a final elongation step
at 72 °C for 3 min. PCR products (10 µl) were separated by
1.2% agarose gel and quantified using the Phoretix 1D image
analysis software (Phoretix International, Newcastle-upon-
Tyne, UK).
Real-time PCRs were performed on a LightCycler instru-
ment (Roche-Diagnostics, Indianapolis, IN) and with SYBR
Green I, according to the manufacturer’s recommendations.
Cycling conditions were as follows: initial denaturation at 95
°C for 2 min, followed by 40 cycles of denaturation at 95 °C
for 0 s, annealing for 5 s (see Table 1 for annealing tempera-
tures used) and elongation at 72 °C for 15 s. Melting curve
analysis was performed as follows: denaturation at 95 °C for
2 min, annealing at 65 °C for 2 min, followed by a gradual
increase (0.1 °C/s) in temperature to 95 °C. Real-time PCR
efficiencies were evaluated by calculating the slope of a lin-
ear regression graph following recommended protocols. For
each experiment, crossing points were calculated by the
LightCycler Data Analysis Program (LightCycler-3.5 Soft-
ware). Target gene expression levels were normalized with
respect to β-actin expression. Mean crossing point deviations
were calculated between samples and controls as specified in
the figures. For comparative studies of in vivo gene expres-
sion between rd1 and control retinas, 10 retinas were pooled
679
TABLE 1. OLIGONUCLEOTIDES USED FOR RT-PCR
                                               Annealing    Product    GenBank
                   Forward and reverse        temperature   length    accession
    Gene       primer sequences (5' to 3')       (°C)        (bp)      number       Application
------------   ----------------------------   -----------   -------   ---------   ----------------
ABCR           F: ACTTCACCCTCTACCTACCACAC         57          355     AF000149    Standard RT-PCR
               R: GAACAACCTTCACCACCAAGCC                                          (Figure 1F)
β-actin        F: AAAGACCTCTATGCCAACACAG          57          296     M12481      Standard and
               R: AAAGAAAGGGTGTAAAACGCAG                                          real time RT-PCR
                                                                                  (Figure 1F)
GDNF           F: ACCAGATAAACAAGCGGCAG            60          402     XM122804    Real time RT-PCR
               R: TCAGATACATCCACACCGTTTAG                                         (Figure 1B)
GFRα-1         F: GCAAGGAAACCAACTTCAGC            54          202     AF014117    Real time RT-PCR
               R: TCGTATGGGGAATCTTCCAG                                            (Figure 1C)
GFRα-1         F: GAAGATTCCCCATACGAGCC            60          535     AF014117    Standard RT-PCR
               R: TGCCAATCAGTCCCGAGTAG                                            (Figure 1F)
GFRα-2         F: CCTGAACGACAACTGCAAGA            50          246     AF002701    Real time RT-PCR
               R: CAGTTGGGCTTCTCCTTGTC                                            (Figure 1E)
GLAST          F: GAAGGGGAGGCAACCTGAAATGAG        56          287     D63816      Standard RT-PCR
               R: AAGGGGGAGTGGGAAAATGAAAA                                         (Figure 1F)
GLAST          F: GAAGTCTCCCAGACGTTCTAATCC        58          303     D63816      Real time RT-PCR
               R: GCTCTGAAACCGCCACTTACTATC                                        (Figure 2)
Ret            F: ATCCACACCTTCGGACTCAC            54          201     AF209436    Real time RT-PCR
               R: AACCCAGTGCTAGTGCCATC                                            (Figure 1D)
Ret            F: AGTATGCCAAGTATGGCTCTCTG         60          403     AF209436    Standard RT-PCR
               R: ACTCCAAAGGACCACACATCAC                                          (Figure 1F)
Rod arrestin   F: CTATTACGTCAAGCCTGTAGCC          56          434     M24086      Real time RT-PCR
               R: CATCCTCATCTTTCTTCCCTTC                                          (Figure 1A)
This table lists all the oligonucleotides used for RT-PCR in this study with the corresponding annealing temperatures, PCR product lengths,
and Genbank accession numbers.for each age (PN1, PN8, PN15, PN35) and each strain. The
amplification steps were performed in triplicate for each point
and were repeated using three independent cDNA prepara-
tions. The levels of expression of rhodopsin, rod arrestin, and
other markers of retinal degeneration were tested and found
to be in accordance with the age and genotype analyzed, thus
validating our RNA preparations (see Figure 1A for in vivo
mRNA expression study of rod arrestin).
Immunohistochemistry:  rd1 mice were killed 48 h after
being injected (n=10). GDNF- and PBS-treated eyes were
immediately removed, fixed in 4% paraformaldehyde for 6 h
at 4 °C. Eyes were then embedded in paraffin. Sections (6
µm) were cut in a transverse plane using a microtome (model
HM340E; Microm International GmbH, Walldorf, Germany).
Sections were saturated in PBS containing 3% BSA and 0.1%
Tween 20 for 1 h and then incubated overnight at 4 °C with
guinea pig anti-GLAST polyclonal antibody (1:4000; AB1782,
Chemicon International, Temecula, CA). The primary anti-
body was localized using goat anti-guinea pig antibody coupled
with Alexa Fluor 594 (1:1000; Molecular Probes, Leiden,
Netherlands). No immunoreactivity was observed when anti-
GLAST antibody was preabsorbed with GLAST immunizing
peptide (Sigma Genosys, The Woodlands, TX). Confocal mi-
croscopy was performed using a TCS-SP Leica microscope
(Leica Microsystems Inc., Bannockburn, IL), equipped with
a 40x objective (plan apo; NA=1.25). The same parameters
and exposure times were used in all cases. For each optical
section, the signal was treated by line averaging to integrate
the signal collected over four lines in order to reduce noise. A
focal series was collected for each specimen (11 optical sec-
tions per specimen).
Protein extraction and immunoblotting:  rd1 and control
mice were killed at PN1, PN8, PN15, PN21, and PN35 (3
animals per age and strain). Eyes were immediately enucle-
ated, and retinas dissected within 2 min in sterile PBS. Reti-
nas were then homogenized in a lysis buffer containing 50
mM Tris-HCl pH 7.5, 1 mM PMSF, 1 mM EDTA, 1 mM
dithiothreitol, 1% Triton X-100, 1X mixture of protease in-
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Figure 1. Rod arrestin, GDNF, GFRα-1, Ret, and GFRα-2 mRNA expression in the rd1 retina.  In vivo levels of rod arrestin (A), GDNF (B),
GFRα-1 (C), Ret (D), and GFRα-2 (E) mRNA expression were measured in rd1 and wild-type retinas during rod degeneration (PN8, PN15,
and PN35) using semi-quantitative real-time RT-PCR. Bars represent the mean of triplicate determinations; the error bars represent the stan-
dard error of the mean. The open bars represent wild-type mice, and the solid black bars represent rd1 mice. These graphs show data relative
to the lowest value of PN8 control and not relative to the mean value of PN8 control. In the case of rod arrestin (A), expression data was plotted
relative to the lowest value obtained, regardless of the age or strain. Concerning markers of rod photoreceptors, the lowest value was observed
in 35-day-old rd1 mouse retinas because there are no more surviving rods then. Therefore, rod arrestin data were expressed in comparison to
PN35 rd1 retinas. F: Gel electrophoresis of PCR products after amplification of first-strand cDNA from pure Müller glial cell (MGC) cultures
and mixed retinal cell cultures. PCR products for β-actin (296 bp), GLAST (287 bp), ABCR (355 bp), Ret (403 bp), and GFRα-1 (535 bp) of
the correct and indicated sizes were obtained. Results are representative of three experiments.
680hibitors, 45 µg/ml TLCK, 1 mM sodium fluoride, and 1 mM
sodium orthovanadate. Protein concentrations were estimated
by Bradford’s technique [35]. Proteins were shock-frozen and
maintained at -80 °C until analysis. Proteins were further di-
luted 1:1 in sample buffer (final concentrations: 10 mM Tris-
HCl pH 8, 1 mM EDTA, 20 mM dithiothreitol, 3% SDS, 10%
glycerol, 0.1% bromophenol blue, 4 M urea) and heated at 50
°C for 45 min. Proteins (10 µg/lane) were separated by 10%
SDS-PAGE gel electrophoresis containing 4 M urea, and trans-
ferred onto nitrocellulose membranes. Membranes were
blocked with PBS, 0.1% Tween 20, 3% nonfat dry milk, and
5% horse serum overnight at 4 °C and then incubated with
anti-GLAST antibody (1:15000) for 2 h at room temperature.
Membranes were washed and incubated with the appropriate
horseradish peroxidase-labeled secondary antibody (1:15000;
Jackson ImmunoResearch Laboratories, West Grove, PA) for
1 h at room temperature. Antibody binding was visualized by
a chemiluminescence detection system (ECL+, Amersham,
Arlington Heights, IL) as recommended by the manufacturer.
To ensure that equal quantities were loaded in each lane, mem-
branes were stripped and subsequently reprobed with mono-
clonal anti-α-tubulin antibody (1:500; T5168, Sigma, Saint
Louis, MO). Alternatively, an identical gel was run in parallel
and subjected to Coomassie staining to control equal loading.
Band intensities were quantified by scanning densitometry
using Phoretix 1D software.
GDNF quantification:  GDNF protein levels in untreated
rd1 and control retinas at PN15 were measured by enzyme-
linked immunosorbant assay (ELISA) according to the
manufacturer’s instructions (GDNF-Emax ImmunoAssay
System, Promega, Madison, WI).
Quantification of free amino acids:  Retinas were rapidly
dissected on ice and deproteinized with 10% (w/v) trichloro-
acetic acid containing 0.5 mM EDTA. After sonication and
centrifugation, supernatants were collected and stored at -80
°C until amino acid analysis. Amino acids were separated and
quantified by ion exchange chromatography using an amino
acid analyzer (AminoTac JLC-500/V; JEOL, Tokyo, Japan).
The concentrations of each amino acid are expressed, as a
percentage, with respect to the sum of all the concentrations
of the amino acids quantified by the analyzer (which include
taurine, threonine, serine, asparagine, glutamate, glutamine,
glycine, alanine, citrulline, valine, isoleucine, leucine, tyrosine,
phenylalanine, ornithine, lysine, and arginine).
Statistical analysis:  All data are presented as the mean
and the standard error of the mean (SEM). Unpaired Student’s
t-test was used to compare amino acid levels in rd1 and con-
trol mice and to compare GLAST mRNA expression in GDNF-
and PBS-treated MGC. Paired Student’s t-test was used to
compare GLAST protein expression in GDNF- and PBS-
treated eyes both in retinal organ cultures and in vivo. Values
of p<0.05 were considered to be significant.
RESULTS
GDNF expression during photoreceptor degeneration in the
rd1 mouse retina: A review of the literature enabled us to de-
termine that (1) PN8 most likely represents the first time point
when the degenerative process becomes detectable in the rd1
mouse retina [32,36-40], (2) PN35 can be considered as the
terminal stage of rod degeneration [41], and (3) PN15 repre-
sents an intermediate stage between the two [42].
We confirmed these data by studying rod arrestin mRNA
relative expression between rd1 and control retinas using quan-
titative RT-PCR (Figure 1A). At PN8 (corresponding to the
onset of photoreceptor degeneration), no difference was no-
ticed between rd1 and control retinas. At PN15 (correspond-
ing to an intermediate stage of degeneration), rd1 mouse reti-
nas expressed 2.8 fold less rod arrestin mRNA than did con-
trols and at PN35 (representing the terminal stage of rod de-
generation), over 14 fold less.
As GDNF has recently been shown to be upregulated en-
dogenously in a model of light-induced retinal degeneration
[20], we examined GDNF mRNA expression in rd1 and con-
trol mouse retinas during rod photoreceptor degeneration us-
ing real-time RT-PCR selecting times corresponding to early,
intermediate, and terminal phases of degeneration as above
(Figure 1B). At PN8, no difference was noticed between rd1
and control retinas. At PN15, GDNF mRNA expression was
©2005 Molecular Vision Molecular Vision 2005; 11:677-87 <http://www.molvis.org/molvis/v11/a80/>
Figure 2. GLAST mRNA expression in Müller glial cell (MGC) cul-
tures treated with GDNF.  GLAST mRNA levels were studied in
MGC cultures in the presence and absence of GDNF using real-time
RT-PCR. Bars represent the mean of three independent experiments;
the error bars represent the standard error of the mean (asterisk indi-
cates p<0.05, n=3).
6811.35 fold higher in rd1 mice than in controls. At PN35, no
more difference was observed.
We further investigated whether there could be a differ-
ence in GDNF protein expression between the two strains at
PN15, but the level of GDNF protein expression was unde-
tectable at PN15 when measured by ELISA. Our results thus
suggest that GDNF mRNA is moderately and transiently
upregulated at PN15 in the rd1 mouse.
GDNF receptor mRNA expression in the rd1 mouse retina:
GDNF acts through a receptor complex composed of the bind-
ing receptor GFRα-1 and the Ret protein tyrosine kinase
[16,43-45]. We used real-time RT-PCR to study GFRα-1 and
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Figure 3. GLAST protein expression in rd1 mouse retinas in the presence and absence of GDNF.  A,B: GLAST protein levels were studied in
retinal organ cultures (A) and in vivo (B) in the presence and absence of GDNF. Western blots of total proteins (10 µg/lane) prepared from
retinas 48 h after treatment with either GDNF or PBS, were probed with anti-GLAST. The blots demonstrated one band at about 76 kDa
(GLAST monomeric form, labeled 3) and two bands at about 160 kDa (GLAST multimeric forms, labeled 1 and 2). C: GLAST protein was
1.48 times more abundant in GDNF-treated retinal organ cultures than in controls (6 samples per group). In vivo, GLAST protein was 1.25
times more abundant in GDNF-injected retinas than in controls (6 samples per group). Data are presented as the mean and SEM of the values
obtained in three independent experiments (two asterisks indicate p<0.005, three asterisks indicate p<0.0005). D-G: Transverse sections of a
PBS-injected eye and a GDNF-injected eye, from the same rd1 mouse, were examined with a confocal microscope. Sections were analyzed
using the same parameters and exposure times. Pictures were always taken at the same distance from the optic nerve. D: PBS-injected eye,
Nomarski optics. E: PBS-injected eye, immunostaining with anti-GLAST antibody. F: GDNF-injected eye, Nomarski optics. G: GDNF-
injected eye, immunostaining with anti-GLAST antibody. Due to photoreceptor degeneration, the outer nuclear layer (ONL) is no longer
composed of one or two layers of photoreceptors. Pictures are representative of four independent experiments with similar results. The outer
plexiform layer (OPL), inner nuclear layer (INL), inner plexiform layer (IPL), and ganglion cell layer (GCL) are also labeled. The scale bar
represents 20 µm.
Ret mRNA expression in the retinas of rd1 and control mice,
selecting times corresponding to early, intermediate and ter-
minal phases of degeneration as above. In both control and
rd1 mouse retinas, GFRα-1 mRNA expression increased with
age (Figure 1C). However, at each age, the mRNA expression
was significantly higher in rd1 retinas than in controls. At PN8,
GFRα-1 mRNA expression was 1.3 fold higher in rd1 retinas
than in controls. At PN15, the mRNA expression difference
reached a maximum of 2.4 fold. At PN35, GFRα-1 mRNA
increase returned to a 1.5 fold difference. In both strains, Ret
mRNA expression increased with age (Figure 1D). But in con-
trast to GFRα-1, no difference in Ret mRNA expression was
682observed between rd1 and control retinas from PN8 to PN35.
As GDNF signaling through GFRα-2 has also been reported
[46-48], we measured GFRα-2 mRNA expression from PN8
to PN35, but observed no difference between rd1 and control
retinas (Figure 1E). Hence, our results indicated that Ret and
GFRα-2 mRNA expression levels remained stable during rod
degeneration whereas GFRα-1 mRNA is upregulated.
To obtain information on the retinal localization of these
receptors, Ret and GFRα-1 mRNA expression levels were then
compared in pure MGC cultures and in mixed retinal cell cul-
tures (including all types of retinal cells, glial and neuronal)
by using standard RT-PCR (Figure 1F). Figure 1F illustrates
that both Ret and GFRα-1 mRNAs were expressed at higher
levels in pure MGC than in retinal cell cultures. Quantitative
measurements of RT-PCR products demonstrated that in vitro,
in our RT-PCR conditions, Ret and GFRα-1 mRNAs were 1.7
and 5.3 times more abundant in pure MGC than in retinal cells,
respectively, whereas there was no difference in the amount
of housekeeping gene beta-actin mRNA between the two types
of cultures. We quantified the glial glutamate transporter
GLAST and the photoreceptor-specific gene ABCR to assess
the quality of our cultures. GLAST mRNA was 8.7 times more
abundant in MGC cultures than in retinal cell cultures. By
contrast, ABCR mRNA expression was only detected in reti-
nal cell cultures, thus confirming the purity of our MGC cul-
tures. The comparison of GFRα-1 and GLAST mRNA ex-
pression ratios between MGC and mixed retinal cells suggested
that GFRα-1 was not exclusively, like GLAST, but predomi-
nantly expressed in MGC whereas Ret was more widely dis-
tributed in retinal cells including MGC.
Exogenous administration of GDNF enhances GLAST ex-
pression:  Since retinal MGC express GDNF receptors (Fig-
ure 1) and GDNF upregulates the expression of the glial
glutamate transporter GLAST in the brain [24] and in a model
of glaucoma [25], we next investigated whether exogenous
GDNF could modulate GLAST expression by MGC in the
rd1 retina. The effect of GDNF on GLAST mRNA expression
was first studied in vitro in pure MGC cultures. MGC cultures
were treated with or without GDNF for 24 h. RNAs were then
extracted and GLAST mRNA levels were analyzed by real-
time RT-PCR. Figure 2 shows that GDNF-treated MGC ex-
pressed 5.5 fold more GLAST mRNA than did untreated MGC
(SEM 1.8, n=3; p<0.05).
To further confirm that GDNF upregulates GLAST ex-
pression, we studied GLAST protein levels in retinal organ
cultures and in vivo, in the presence and absence of GDNF.
As previously reported [49-51], GLAST immunoblots showed
different immunoreactive bands corresponding to monomeric
(about 76 kDa) and multimeric forms (about 160 kDa) of
GLAST. Figure 3A illustrates that GDNF treatment increased
GLAST protein expression in rd1 retinal organ cultures. Den-
sitometric analysis of band intensities (monomeric and
multimeric forms) revealed that GLAST protein levels were
1.48 fold higher in GDNF-treated explants than in paired con-
trols (SEM 0.1, n=6, p<0.005; Figure 3C). GLAST expres-
sion levels were measured in vivo after subretinal injection of
either GDNF or PBS. Immunoblot analyses confirmed the
GDNF-induced increase in GLAST (Figure 3B). Figure 3C
illustrates that, on average, 1.25 times more GLAST was
present in rd1 GDNF-injected eyes than in controls (SEM 0.02,
n=6, p<0.0005).
Immunoreactivity experiments have shown that GLAST
is present on MGC membranes and processes throughout the
whole retina, with more intense labeling in both the outer lim-
iting membrane and the outer plexiform layer [26,27]. Immu-
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Figure 4. Free glutamate and glutamine levels in rd1 and control
retinas after subretinal injection of GDNF or PBS.  Free glutamate
(A) and glutamine (B) levels were measured in rd1 and control reti-
nas at PN15 and PN21, 48 h after subretinal injection of either GDNF
or PBS. The bars represent the mean proportion (as a percentage) of
amino acids that are glutamine and glutamate. Bars represent the
mean (n=11); the error bars represent the standard error of the mean.
683nohistochemical analyses of rd1 mice after in vivo subretinal
injection of either GDNF or PBS showed a similar immunore-
activity across the whole retina corresponding to MGC (Fig-
ures 3E and 3G) [26,27]. However, both in GDNF- and PBS-
treated eyes, the staining appeared more intense in the outer
nuclear layer around the degenerating photoreceptors (Figure
3E,G). In addition, GDNF injection increased GLAST label-
ing throughout the whole tissue, with more conspicuous la-
beling around the degenerating photoreceptors. Because of the
resolution limit in confocal microscopy, we could not deter-
mine whether the observed increase in GLAST labeling was
located at the membrane or in the cytoplasm (reticulum).
Our data show that GDNF upregulated GLAST expres-
sion in MGC cultures, in retinal organ cultures and in vivo,
particularly around photoreceptors.
GDNF-induced upregulation of GLAST does not signifi-
cantly modify free glutamate and glutamine levels in the de-
generating rd1 retina: We demonstrated, in a parallel work,
that free glutamate level increases during rod degeneration in
the rd1 retina and is toxic to rods [30]. In the present study, we
showed that neuroprotective GDNF enhanced GLAST expres-
sion particularly around photoreceptors (Figure 2 and Figure
3). Hence we next investigated whether GDNF treatment could
decrease glutamate level in rd1 retinas and, at the same time,
increase the level of one of its metabolite: glutamine. Subretinal
injections of GDNF or PBS were performed on 15-day-old
and 21-day-old rd1 mice. Retinal amino acid levels were mea-
sured 48 h after injection. GDNF treatment did not alter free
glutamate and glutamine levels at PN15 or PN21 (Figure 4).
DISCUSSION
 Our results can be summarized as follows: (1) In the rd1 retina,
GDNF receptor mRNAs did not decrease during photorecep-
tor degeneration and were expressed by MGC. (2) GDNF ap-
plication to MGC cultures, rd1 mouse retinal explants, and
rd1 mouse retinas in vivo enhanced the expression of GLAST.
GLAST protein expression in MGC was particularly increased
around degenerative photoreceptors. (3) Free glutamate and
glutamine levels in the rd1 retina were not significantly modi-
fied by exogenous GDNF.
A potential indirect neuroprotective pathway for GDNF:
In the retina, we demonstrated that exogenous GDNF induces
histological and, more importantly, functional protection of
photoreceptors in the rd1 mouse [8], as documented since then
in other models of photoreceptor degeneration [9-11]. The
mechanisms underlying GDNF neuroprotection remain un-
known. In vitro, a direct survival-promoting effect on new-
born rodent photoreceptors was observed [16,17]. Now, sev-
eral arguments support the hypothesis that GDNF exerts its
trophic effect on photoreceptors in the rd1 mouse also indi-
rectly through activation of intermediate MGC.
First, our results indicate that GDNF receptors, GFRα-1
and Ret, were not exclusively expressed by the degenerating
photoreceptor cells in the rd1 retina since both GFRα-1 and
Ret mRNA levels in vivo are not reduced by photoreceptor
degeneration (Figure 1C,D). Ret mRNA expression, on the
one hand, is not altered by the degeneration process in accor-
dance with its immunohistochemical localization in the whole
retina [52]. GFRα-1 localization in the retina, on the other
hand, is still a matter of debate. Conflicting data have been
reported, GFRα-1 has been localized in MGC, in the inner
plexiform layer and retinal ganglion layer, with a weak stain-
ing also being observed in photoreceptor outer segments by
some authors [53] or restricted to the outer nuclear layer by
others [19,20]. Such discrepancies in immunohistochemical
observations might come from the use of different antibodies.
Here our results demonstrate that GFRα-1 mRNA expression
did not decrease as one could have expected if its expression
had been restricted to photoreceptors, but, on the contrary, in-
creases in the rd1 mouse retina during and after complete rod
degeneration (Figure 1C). This implies that GFRα-1 mRNA
is not exclusively expressed by photoreceptor cells, at least in
the degenerative retina.
Second, our comparative in vitro experiments further dem-
onstrate that GFRα-1 mRNA was predominantly expressed
by MGC, whereas Ret mRNA was more widely distributed
among cultured retinal cells (Figure 1F).
Therefore, all our observations suggest that GDNF could
exert its trophic effect on photoreceptors in the rd1 mouse
retina through an indirect pathway via MGC.
The presence of GDNF receptors in MGC is further sup-
ported by the GDNF-induced changes in these cells. For in-
stance, we have previously demonstrated that subretinal in-
jection of GDNF increases glial fibrillar acidic protein (GFAP)
immunoreactivity, a MGC marker, in the rd1 mouse, thus im-
plying that MGC are activated after GDNF treatment [8].
GDNF also stimulates the expression of endogenous trophic
factors in MGC cultures [20]. Here we further confirmed the
glial activation by demonstrating a GDNF-elicited increase in
GLAST protein surrounding degenerating photoreceptors in
the rd1 retina (Figure 2 and Figure 3).
Does neuroprotective GDNF promote endogenous anti-
excitotoxic mechanisms?:  We demonstrated, in a parallel ar-
ticle, that glutamate-mediated excitotoxic mechanisms occur
in the degenerating rd1 retina and contribute to rod cell death
[30]. These results are consistent with the data reported here.
First, Marco et al. [54] observed that, in the striatum, in-
jection of excitatory amino acids: (1) induced an early and
transient increase of GDNF mRNA expression, (2) clearly
upregulated intrastriatal GFRα-1 mRNA, (3) and did not
modify GFRα-2 mRNA levels.
As shown in Figure 1B,C,E we obtained similar profiles
of expression during the degenerative process. Hence, although
endogenous GDNF was only moderately and transiently in-
creased, our observations suggest that GDNF-activated path-
ways are upregulated during photoreceptor degeneration in
the rd1 retina, possibly in relation to the alterations in glutamate
metabolism we described [30].
Second, the observed upregulation of GLAST (which rep-
resents a key element in glutamate clearance) following GDNF
neuroprotective treatment (Figure 2 and Figure 3) strength-
ened the hypothesis of a toxic glutamate increase during pho-
toreceptor degeneration in the rd1 mouse.
In the brain, GDNF is neuroprotective in both acute and
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684chronic neurodegenerative disorders [55,56] including an
excitotoxic model of Huntington’s disease [21]. Therefore, it
was worth investigating whether GDNF could exert its
neuroprotective effect on photoreceptors in the rd1 retina, at
least partially, by promoting an endogenous anti-glutamate-
mediated excitotoxic mechanism, that is, an upregulation of
GLAST.
In order to determine whether GDNF promoted photore-
ceptor survival through such a mechanism, we next measured
free amino acid levels in rd1 retinas following GDNF or PBS
treatment. As shown in Figure 4, we failed to demonstrate a
significative modification of glutamate and glutamine levels
in GDNF-treated retinas when compared to controls. Two main
explanations can be put forward for such results. First, the
upregulation of GLAST may not be sufficient to prevent
glutamate levels from rising. Second, our free amino acid
measurements reflected both extra- and intracellular contents
of whole rd1 retinas, hence displacement of glutamate from
one cellular compartment to another (from the extracellular
environment of photoreceptors to the cytoplasm of MGC
through GLAST) without metabolism of glutamate into
glutamine by glutamine synthetase could not be demonstrated.
Thus, we could not formally establish nor rule out that
glutamate levels were effectively modified around photore-
ceptors.
Our results altogether shed some light on the central role
of MGC in the neuroprotective response linked to GDNF in
the rd1 retina. Numerous published studies have dealt with
the identification of trophic factors promoting photoreceptor
survival, but only few of them focused on the mechanisms
underlying trophic factor neuroprotective effects. Undoubt-
edly, understanding of these mechanisms would lead to new
pharmacological approaches in RP. Further work is certainly
needed to better understand the mode of action of GDNF on
glial and rod photoreceptor cells and to design refined phar-
macological intervention in the rod degenerative process.
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